34 results about "Malignant phenotype" patented technology

The invention belongs to the technical field of biological medicine and molecular biology, and provides application of GJB6 in preparation of an esophageal squamous cell carcinoma prognosis evaluation reagent and screening of drugs for targeted treatment of esophageal squamous cell carcinoma. The low expression of the GJB6 is applied to preparation of an esophageal squamous cell carcinoma prognosis evaluation reagent. GJB6 is low in expression in ESCC patients, and ESCC prognosis is poor. And the prognosis of patients with high expression of GJB6 is better. Overexpression of GJB6 inhibits ESCC cell proliferation, migration and invasion and in-vivo tumor enlargement. The GJB6 plays a role of a cancer suppressor gene in ESCC and inhibits cell proliferation, migration and invasion. The AKT signal channel is one of downstream channels for GJB6 to regulate the occurrence and development of ESCC. The AKT inhibitor effectively inhibits GJB6 low-expression ESCC malignant phenotypes, including enhancement of cell proliferation and migration invasion ability and in-vivo tumor enlargement. The AKT is a key therapeutic target of the GJB6 low expression type ESCC.

The present invention pertains to the technical field of biomedicine, and specifically relates to a gene delivery system and use thereof in the preparation of a tumor therapeutic drug. The present invention relates to a technical means for inducing differentiation of tumor cells into mature cells, which utilizes messenger ribonucleic acid to regulate the expression of HNF4α in tumor cells, inhibits the malignant phenotype of malignant solid tumor cells, and achieves the effect of treating malignant solid tumors, thereby being applied to a preparation method and use of a solid tumor drug.

The application relates to the technical field of medicines, and discloses an application of homoharringtonine in the preparation of a medicine for treating small cell lung cancer, and further provides a medicine for treating small cell lung cancer and containing homoharringtonine. The application discloses an action mechanism of homoharringtonine, an active ingredient of traditional Chinese medicine, against SCLC, and discloses that the traditional Chinese medicine ingredient HHT inhibits a malignant phenotype by targeting tumor-specific glycosylation enzyme MGAT5, provides an innovative perspective of glyco-biology for the research of traditional Chinese medicine against tumors, provides an important scientific basis for the subsequent development and application of homoharringtonine, and provides a new medicine treatment approach for treating small cell lung cancer.

The invention relates to a mouse liver cancer cell P1-Hepa1-6 capable of simulating human liver cancer metabolism reprogramming characteristics and application thereof, and belongs to the technical field of biotechnology and medicine. The invention provides a mouse liver cancer cell P1-Hepa1-6 which is preserved in the China Center for Type Culture Collection on November 12, 2025, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: C202586. The invention further provides a preparation method of the mouse liver cancer cell P1-Hepa1-6. The mouse liver cancer cell P1-Hepa1-6 has the advantages that the mouse liver cancer cell P1-Hepa1-6 can be used for preparing the mouse liver cancer cell P1-Hepa1-6; the mouse liver cancer cell P1-Hepa1-6 has high malignant phenotype, can simulate human liver cancer metabolism reprogramming characteristics, is high in pertinence and good in repeatability, and has important application value and market prospect in the fields of liver cancer basic research, drug target discovery, preclinical efficacy evaluation and the like.

The invention discloses application of a lipid synthesis inhibitor in treatment of breast cancer. Researches prove that F.n colonization exists in breast cancer tissues, and the F.n can regulate and control lipid deposition related gene expression and lipid metabolism change of tumor-related macrophages, so that lipid deposition of the macrophages and proliferation, invasion and migration capabilities of tumor cells are promoted; after the lipid deposition inhibitor is added, the lipid metabolism disorder of the tumor-associated macrophages can be inhibited, the tumor malignant phenotype is finally inhibited, and the treatment of the breast cancer is realized. The invention provides a new potential therapeutic target and a new therapeutic drug for effective treatment of breast cancer.

This invention discloses a photothermal synergistic tumor stem cell inhibition system, its preparation method, and its applications. Addressing the current lack of effective treatments for large / unresectable GBM and its strongly immunosuppressive microenvironment, this invention constructs an injectable hydrogel platform (MIN-PPIC@iGel) integrating multiple key functions. This platform achieves a synergistic therapeutic model involving photothermal ablation for local tumor reduction, inhibition of residual GBM stem cells (GSCs), and activation of dendritic cells (DCs)-mediated anti-tumor immunity. Cellular experiments show that this invention can synergistically kill GL261 cells, significantly inhibit tumor stem cells and malignant phenotypes, induce significant ICD, and enhance DC maturation and activation effects. In a large-volume orthotopic GBM mouse model, a single intratumoral injection of MIN-PPIC@iGel combined with short-term near-infrared light irradiation doubled survival; further combination with antibody therapy unexpectedly achieved long-term tumor-free survival in 50% of mice, providing a new strategy for the local treatment of unresectable GBM.

A gene delivery system and applications thereof in the technical field of biological medicines that is particularly useful in the preparation of drugs for treatment of tumors are disclosed. The gene delivery system and applications relate to technology for inducing the differentiation of malignant tumor cells into mature cells, in which regulating the expression of HNF4 alpha protein in the malignant tumor cells using messenger ribonucleic acid, the malignant phenotype of the malignant solid tumor cells is inhibited, and the effective treatment of the malignant solid tumors is achieved. The gene delivery system and applications are therefore applicable to a method of preparing a drug for treating malignant solid tumors and to a method of treating a patient having a malignant solid tumor.

The application discloses application of an HTRA1 inhibitor in preparation of a drug for treating pancreatitis-cancer transformation, and belongs to the technical field of medicines.The HTRA1 inhibitor is screened through a drug database, the HTRA1 inhibitor is used to treat a pancreatic cancer cell line and a mouse pancreatitis-cancer transformation in-vivo model, it is proved that the HTRA1 inhibitor Carfilzomib can inhibit the malignant phenotype of Panc1 cells in vitro, and can inhibit the transformation of a KC mouse stimulated by cerulean into a pancreatic ductal adenocarcinoma in vivo, and the application provides a basis for using the HTRA1 inhibitor as the drug for treating pancreatitis-cancer transformation.

The application discloses application of a small-molecule compound for inhibiting HNF4 alpha degradation in preparation of a liver cancer treatment drug. The structural general formula of the small-molecule compound for inhibiting HNF4 alpha degradation is shown in the following formula: the small-molecule compound for inhibiting HNF4 alpha degradation provided by the application can play the biological effects of correcting glycolipid metabolism disorder of the liver, reducing liver fibrosis and inhibiting malignant phenotypes of liver cancer, and is applied to clinical treatment of chronic liver diseases and liver cancer.

The invention relates to the technical field of biomedicine, in particular to application of RAB26 as a prognosis evaluation marker and a treatment target of osteosarcoma. System research finds that RAB26 has significant differential expression between osteosarcoma primary lesion and metastasis lesion, high expression of RAB26 is closely related to poor overall lifetime and event-free lifetime of patients, and RAB26 can be used as an effective biomarker for evaluating osteosarcoma development risk and prognosis state. The RAB26 quantitative detection scheme established by the invention can accurately reflect the real change of RAB26 in tumor tissues or related samples, and provides a reliable basis for risk stratification, disease monitoring and prognosis judgment of clinical patients. On the other hand, the invention clarifies that RAB26 activates autophagy by up-regulating PDCD6IP and inhibiting an mTOR signal channel for the first time, so that the invasion and migration capabilities of osteosarcoma cells are enhanced, and malignant phenotypes of the cells can be remarkably weakened by inhibiting and intervening RAB26.

The application discloses application of FH acetylation in diagnosis, staging, treatment and prognosis prediction of colorectal cancer (CRC). The application screens acetylated non-histone proteins and acetylation sites related to CRC in a systematic manner, and for the first time finds that FH K80 acetylation modification level regulates the malignant phenotype of CRC, the FH K80 acetylation modification level presents significant difference in CRC patients, and is related to prognosis, and a high acetylation state (FH K80Q) can inhibit the proliferation, migration and invasion of CRC cells. The application provides a new direction for diagnosis, prognosis prediction and effective treatment of CRC, and has a wide application prospect in clinic.

The invention is applicable to the technical field of biology, and provides bionic hydrogel for culturing tongue cancer organoid and application. The bionic hydrogel is prepared by taking type I collagen, alginate and periostin polypeptide as cores according to the microenvironment characteristics of tongue cancer, and is adapted to the mechanical characteristics of tongue squamous cell carcinoma tissues and the three-dimensional growth space requirements of organoids in the physical aspect; in the biochemical level, the tongue cancer microenvironment is accurately simulated by virtue of the effects of promoting cell adhesion of the I-type collagen and maintaining the dryness of the cancer cells by virtue of the periostin polypeptide, so that a complete culture method is formed. The bionic hydrogel is stable in property and capable of supporting the culture requirement for a long time and enhancing the interaction between cells and a matrix so as to improve the cell adhesion capacity, the cultured tongue cancer organoid can well maintain the heterogeneity and tumor malignant phenotype of tongue cancer cells, and the bionic effect of the organoid is optimized. The result provides a high-precision in-vitro model for tongue cancer drug screening, chemotherapy sensitivity prediction and individualized treatment, and has practical application value.

The invention belongs to the technical field of biological medicines, and relates to application of small nucleolus SnoRD89 in preparation of an ovarian cancer targeting drug. The invention discloses that SnoRD89 inhibits the malignant phenotype of ovarian cancer cells by influencing the RPL11 / MDM2 / P53 pathway for the first time. The invention finds a new effective method for targeted regulation and control of apoptosis signal channels, that is, ovarian cancer cell apoptosis is induced through siRNA of targeted SnoRD89, and the method is applied to basic medical research.

The application belongs to the technical field of biotechnology, and provides a biomimetic hydrogel for tongue cancer organoid culture and application.According to the characteristics of the tongue cancer microenvironment, the biomimetic hydrogel is prepared by taking collagen type I, alginate and periostin polypeptide as the core, the mechanical characteristics of tongue squamous cell carcinoma tissue and the three-dimensional growth space requirements of organoids are adapted on the physical level, the tongue cancer microenvironment is precisely simulated on the biochemical level by relying on the cell adhesion promotion of collagen type I and the role of periostin polypeptide in maintaining the stemness of cancer cells, and a complete culture method is formed.The biomimetic hydrogel is stable in nature, can support the culture requirements for a long time, can enhance the interaction between cells and the matrix to improve the cell adhesion capacity, and the tongue cancer organoids cultured by the biomimetic hydrogel can well retain the heterogeneity of tongue cancer cells and the malignant phenotype of tumors, and the biomimetic effect of the organoids is optimized.The achievement provides a high-precision in-vitro model for tongue cancer drug screening, chemotherapy sensitivity prediction and individualized treatment, and has practical application value.

A gene delivery system and applications thereof in the technical field of biological medicines that is particularly useful in the preparation of drugs for treatment of tumors are disclosed. The gene delivery system and applications relate to technology for inducing the differentiation of malignant tumor cells into mature cells, in which regulating the expression of HNF4 alpha protein in the malignant tumor cells using messenger ribonucleic acid, the malignant phenotype of the malignant solid tumor cells is inhibited, and the effective treatment of the malignant solid tumors is achieved. The gene delivery system and applications are therefore applicable to a method of preparing a drug for treating malignant solid tumors and to a method of treating a patient having a malignant solid tumor.

A gene delivery system and applications thereof in the technical field of biological medicines that is particularly useful in the preparation of drugs for treatment of tumors are disclosed. The gene delivery system and applications relate to technology for inducing the differentiation of malignant tumor cells into mature cells, in which regulating the expression of HNF4 alpha protein in the malignant tumor cells using messenger ribonucleic acid, the malignant phenotype of the malignant solid tumor cells is inhibited, and the effective treatment of the malignant solid tumors is achieved. The gene delivery system and applications are therefore applicable to a method of preparing a drug for treating malignant solid tumors and to a method of treating a patient having a malignant solid tumor.

The invention discloses a shRNA (short hairpin Ribonucleic Acid) interference library for inhibiting expression of CT45A3, a vector and application of the shRNA interference library in anti-colon cancer drugs, and belongs to the technical field of gene drugs. The shRNA interference library comprises one or more of the sequences as shown in SEQ ID NO.1-3. The invention also discloses a method for preparing the shRNA interference library. The shRNA interference library or the expression vector thereof can efficiently and specifically down-regulate the expression level of CT45A3 in colorectal cancer cells, so that abnormal activation of a downstream cancer promoting signal channel mediated by the shRNA interference library or the expression vector is blocked, and the development of malignant phenotypes is remarkably inhibited. The shRNA interference library has potential clinical application value in targeted therapy of colorectal cancer.

The invention discloses application of a small molecule compound for inhibiting degradation of HNF4alpha in preparation of a medicine for treating liver cancer. The structural general formula of the small molecule compound for inhibiting the degradation of the HNF4alpha is shown in the specification, the small molecule compound for inhibiting degradation of the HNF4alpha can play the biological effects of correcting liver glycolipid metabolism disorder, relieving liver fibrosis and inhibiting liver cancer malignant phenotypes, and is applied to clinical treatment of chronic liver diseases and liver cancer.

This invention discloses the application of TBC1D8, a member of the TBC1 domain family, in the preparation of predictive biomarkers for prognosis and immunotherapy responsiveness in human colorectal cancer patients. This invention evaluated the correlation between TBC1D8 levels and clinical characteristics and its biological functions using next-generation sequencing results from the TCGA database and in vitro and in vivo experiments. The results showed that elevated TBC1D8 levels were associated with poor prognosis in colorectal cancer patients. Experimental studies also observed that TBC1D8 is associated with a hypoxic microenvironment and may participate in regulating the malignant phenotype of colorectal cancer cells and tumor cell stemness. Furthermore, TBC1D8 is closely related to the infiltration of immunosuppressive macrophages; experiments showed that knocking down TBC1D8 significantly inhibited the differentiation and infiltration of immunosuppressive macrophages. Therefore, TBC1D8 can serve as a prognostic biomarker for colorectal cancer patients and may also be a novel therapeutic target for human colorectal cancer.

The application discloses a new application of m6A modified gene GAS6 and its receptor MERTK in rheumatoid arthritis. Multi-omics integrated analysis of synovial tissue and peripheral blood mononuclear cells of RA patients reveals common dysregulation of transcriptomics and epitranscriptomics, highlighting genes with both differential expression and m6A modification, which are enriched in processes such as phagocytosis, Th17 differentiation and cell aging. Among these genes, GAS6 shows the most significant m6A hypermethylation and expression up-regulation, and is verified as a key effector molecule interacting with MERTK / AXL receptor. Functional experiments show that GAS6 and MERTK synergistically promote the malignant phenotype of RA fibroblast-like synoviocytes, enhance their proliferation, migration, inflammatory cytokine secretion and anti-apoptotic ability.

The invention provides application of novel burkholderia cepacia as a marker for tumor diagnosis, screening, prediction or prognosis. The invention provides a qualitative and quantitative detection method for detecting the Burkholderia cenocepacia bacteria in the glioma for the first time. On one hand, through co-culture with Burkholderia cenocepacia bacteria, the malignant phenotypic capabilities of proliferation, invasion and the like of glioma cells can be remarkably enhanced; more importantly, the abundance value of the 16S rRNA gene of the Burkholderia cenocepacia bacteria can be used as a molecular marker for prognosis evaluation of the glioma and a target spot for treatment of the glioma. A new thought is provided for diagnosis of glioma, and important clinical value is achieved.

The application discloses a HeLa cell three-dimensional culture model, a preparation method and application. HeLa cells are mixed with a collagen-sodium alginate composite hydrogel precursor solution to obtain a cell-precursor mixture, the cell-precursor mixture is mixed with a CaCl2 solution to obtain a mixed solution, and the mixed solution is placed in an incubator for standing culture for 10-60 min, so that the hydrogel is cross-linked and solidified to form a three-dimensional culture system; complete culture medium is further added for continuous culture, and a HeLa cell three-dimensional culture model is constructed. The HeLa cell three-dimensional culture model is constructed by using the hydrogel, defects existing in simulation of a tumor microenvironment by two-dimensional culture and an animal model are effectively solved, the body microenvironment can be better simulated, cells form regular three-dimensional cell spheroids, a malignant phenotype is maintained, the accuracy and repeatability of drug screening are improved, and a reliable technical platform is provided for cervical cancer mechanism research and anti-tumor drug screening.

The invention discloses sgRNA (small guide ribonucleic acid) targeting METTL1 and application of the sgRNA, relates to the technical field of biology, and particularly provides two sgRNA sequences, namely, sgRNA-001 (5 '-CAAGTGGAGTTTGCAGACAT-3') and sgRNA-002 (5 '-ATAAGCGGAGCAAAGAACT-3'), and a targeting region of the sgRNA sequences is designed to be combined with an NGG PAM sequence of an METTL1 gene, so that accurate editing of a CRISPR / Cas9 system is ensured. By constructing a recombinant lentiviral vector GV708 containing a U6 promoter, Cas9-FLAG, EGFP (Enhanced Green Fluorescent Protein) and a puromycin resistance gene, efficient delivery and stable expression of sgRNA are realized. Experiments show that the sgRNA can effectively silence METTL1 expression, significantly reduce malignant phenotypes of colon cancer cells by inhibiting m7G modified and mediated tumor-related gene stability and signal pathways, and induce enrichment of CD8 + T cells in a tumor microenvironment to generate a synergistic anti-tumor effect.

The invention belongs to the technical field of biological medicine, and provides application of ZNF473 / TRIM28 / EMT as a target in screening of drugs for treating AEJ. The medicine for treating AEJ is an inhibitor for inhibiting or reducing ZNF473 expression, or an inhibitor or a blocking agent for inhibiting or blocking combination of ZNF473 and TRIM28, or an inhibitor for inhibiting EMT expression. Through molecular docking, it is preliminarily proved that ZNF473 is combined with TRIM28. Cell experiments also prove that ZNF473 is combined with TRIM28, and then malignant phenotypes of AEJ are promoted through EMT. The transcription factor plays a key regulation role in cells, and the interaction of the transcription factor plays an important role in the development of tumors and the formation of malignant phenotypes.

The invention belongs to the technical field of biological medicine, and particularly relates to self-replicating RNA for expressing differentiation-related transcription factors and application of the self-replicating RNA in preparation of tumor treatment drugs. The invention relates to a technical means for inducing tumor cells to differentiate into mature cells, expression of important differentiation-related transcription factors in tumor cells is regulated by using messenger ribonucleic acid, malignant phenotypes of malignant solid tumor cells are inhibited, and the effect of treating malignant solid tumors is achieved, so that the messenger ribonucleic acid is applied to the preparation method and application of solid tumor drugs.

The present application relates to the technical field of medicine, and provides application of Ben Dung decoction in preparation of medicine for treating ovarian cancer, wherein the Ben Dung decoction is prepared from licorice, Szechuan lovage rhizome, Chinese angelica, pinellia, radix scrophulariae, radix puerariae, radix paeoniae, ginger and root white bark of prunus mira koehne with a mass ratio of (1.5-2.5):(1.5-2.5):(1.5-2.5):(3-5):(1-3):(6-10):(1.5-2.5):(3-5):(4-7). The Ben Dung decoction can significantly affect the morphology and cycle of ovarian cancer ES-2 and OV-1063 cells, effectively inhibit the malignant phenotypes such as proliferation, migration, infiltration and cloning of the ovarian cancer ES-2 and OV-1063 cells, and inhibit the expression level of CA125 and CEA proteins in the ovarian cancer OV-1063 cells.

The present invention pertains to the technical field of biomedicine, and particularly relates to a self-replicating RNA expressing a differentiation-related transcription factor and use thereof in the preparation of a tumor therapeutic drug. The present invention is a technical means for inducing tumor cells to differentiate into mature cells, which utilizes messenger ribonucleic acid to regulate and control the expression of important differentiation-related transcription factors in tumor cells, inhibits the malignant phenotype of malignant solid tumor cells, and achieves the effect of treating malignant solid tumors, thereby being applied to the preparation methods and use of solid tumor drugs.

The invention belongs to the technical field of cell molecular biology, and particularly relates to a laryngeal squamous cell carcinoma molecular marker and a detection method and application thereof. In order to provide a new way for detecting and treating the laryngeal squamous cell carcinoma, the invention discloses the laryngeal squamous cell carcinoma molecular marker LINC LSAMP-AS1, the sequence of the laryngeal squamous cell carcinoma molecular marker is shown as SEQ ID NO: 1, and the laryngeal squamous cell carcinoma molecular marker LINC LSAMP-AS1 is applied to laryngeal squamous cell carcinoma detection and prognosis judgment; the invention discloses siRNA of a targeted laryngeal squamous cell carcinoma molecular marker, a sense strand and an antisense strand of the siRNA are respectively SEQ ID NO: 4 and SEQ ID NO: 5, the siRNA can knock down the expression level of LINC LSAMP-AS1 in laryngeal squamous cell carcinoma cells, and the siRNA is used for preparing RNA drugs for inhibiting malignant phenotypes of laryngeal squamous cell carcinoma cells.

The invention belongs to the technical field of biological medicines and microorganisms, and particularly relates to an alpha-PD-L1 targeted nano-drug based on a parabacteroides coumarini membrane vesicle and a preparation method and application thereof.The nano-drug is prepared by taking a natural membrane vesicle derived from parabacteroides coumarini as a carrier, connecting an alpha-PD-L1 antibody to the surface of the carrier by adopting a chemical covalent method, and preparing the alpha-PD-L1 targeted nano-drug based on the parabacteroides coumarini membrane vesicle. The functionalized nano drug P-MVs / alpha-PD-L1 is formed; wherein the membrane vesicle carrier is obtained from a bacterial culture supernatant by combining gradient centrifugation with ultracentrifugation; in-vitro experiments show that the nano-drug can effectively inhibit malignant phenotypes such as proliferation, migration and invasion of breast cancer cells; animal in-vivo experiments prove that the nano-drug can significantly inhibit tumor growth and shows good biological safety; in conclusion, the alpha-PD-L1 targeted nano-drug provided by the invention has the advantages of a natural carrier and an immune targeting function, and has a definite application value in the field of breast cancer treatment.